HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $7 price target.
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $7 price target.